168 related articles for article (PubMed ID: 12756634)
1. Effects of the glycoprotein IIb/IIIa antagonist abciximab on thrombus formation and platelet function in cats with arterial injury.
Bright JM; Dowers K; Powers BE
Vet Ther; 2003; 4(1):35-46. PubMed ID: 12756634
[TBL] [Abstract][Full Text] [Related]
2. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
[TBL] [Abstract][Full Text] [Related]
3. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.
Dangas G; Badimon JJ; Coller BS; Fallon JT; Sharma SK; Hayes RM; Meraj P; Ambrose JA; Marmur JD
Arterioscler Thromb Vasc Biol; 1998 Aug; 18(8):1342-9. PubMed ID: 9714143
[TBL] [Abstract][Full Text] [Related]
4. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
Straub A; Wendel HP; Azevedo R; Ziemer G
Eur J Cardiothorac Surg; 2005 Apr; 27(4):617-21. PubMed ID: 15784360
[TBL] [Abstract][Full Text] [Related]
5. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
[TBL] [Abstract][Full Text] [Related]
6. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
Judge HM; Buckland RJ; Holgate CE; Storey RF
Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
[TBL] [Abstract][Full Text] [Related]
7. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
8. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
Nannizzi-Alaimo L; Alves VL; Phillips DR
Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo--in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A.
Klinkhardt U; Kirchmaier CM; Westrup D; Graff J; Mahnel R; Breddin HK; Harder S
Clin Pharmacol Ther; 2000 Mar; 67(3):305-13. PubMed ID: 10741635
[TBL] [Abstract][Full Text] [Related]
11. Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis.
Makkar RR; Litvack F; Eigler NL; Nakamura M; Ivey PA; Forrester JS; Shah PK; Jordan RE; Kaul S
Circulation; 1997 Feb; 95(4):1015-21. PubMed ID: 9054765
[TBL] [Abstract][Full Text] [Related]
12. Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin.
Schneider DJ; Baumann PQ; Holmes MB; Taatjes DJ; Sobel BE
Thromb Haemost; 2001 Feb; 85(2):309-13. PubMed ID: 11246553
[TBL] [Abstract][Full Text] [Related]
13. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
[TBL] [Abstract][Full Text] [Related]
14. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
Quinn MJ; Murphy RT; Dooley M; Foley JB; Fitzgerald DJ
J Pharmacol Exp Ther; 2001 May; 297(2):496-500. PubMed ID: 11303035
[TBL] [Abstract][Full Text] [Related]
15. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
Montalescot G; Barragan P; Wittenberg O; Ecollan P; Elhadad S; Villain P; Boulenc JM; Morice MC; Maillard L; Pansiéri M; Choussat R; Pinton P;
N Engl J Med; 2001 Jun; 344(25):1895-903. PubMed ID: 11419426
[TBL] [Abstract][Full Text] [Related]
16. Effects of GP IIb/IIIa inhibitors on vascular inflammation, coronary microcirculation, and platelet function.
Kereiakes DJ
Rev Cardiovasc Med; 2006; 7 Suppl 4():S3-11. PubMed ID: 17224889
[TBL] [Abstract][Full Text] [Related]
17. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
Keating FK; Whitaker DA; Sobel BE; Schneider DJ
Thromb Res; 2004; 113(1):27-34. PubMed ID: 15081562
[TBL] [Abstract][Full Text] [Related]
18. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
[TBL] [Abstract][Full Text] [Related]
19. Platelets: is aspirin sufficient or must we know how to pronounce abciximab?
Brinkman WT; Terramani TT; Najibi S; Chaikof EL
Semin Vasc Surg; 2002 Dec; 15(4):245-55. PubMed ID: 12478499
[TBL] [Abstract][Full Text] [Related]
20. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates.
Marciniak SJ; Mascelli MA; Furman MI; Michelson AD; Jakubowski JA; Jordan RE; Marchese PJ; Frelinger AL
Thromb Haemost; 2002 Jun; 87(6):1020-5. PubMed ID: 12083481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
